<DOC>
	<DOCNO>NCT02609386</DOCNO>
	<brief_summary>The purpose study determine whether pre-operative regimen study drug , IRX-2 , human cell-derived biologic multiple active cytokine component , plus single dose cyclophosphamide , follow 21 day indomethacin , zinc-containing multivitamin , omeprazole active treatment oral cavity cancer . The regimen intend stimulate immune response cancer .</brief_summary>
	<brief_title>IRX-2 Regimen Patients With Newly Diagnosed Stage II , III , IVA Squamous Cell Carcinoma Oral Cavity</brief_title>
	<detailed_description>This study ass activity safety IRX Regimen participant newly diagnose , untreated , surgically resectable squamous cell cancer oral cavity . Participants randomly assign receive either Regimen 1 : IRX-2 + cyclophosphamide + indomethacin + zinc + omeprazole , Regimen 2 : cyclophosphamide + indomethacin + zinc + omeprazole . The primary study hypothesis Regimen 1 IRX-2 prolongs event-free survival overall survival compare Regimen 2 without IRX-2 . Subjects randomize either Regimen 1 Regimen 2 2:1 basis treat prior surgery .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<criteria>1 . Pathologically confirm ( histology cytology ) Stage II , III , IVA squamous cell cancer oral cavity ( exclude lip ) 2 . Disease surgically resectable curative intent 3 . Hematological function : hemoglobin &gt; 9 g/dL ; lymphocyte count &gt; 500 x 109/mL ; neutrophil count &gt; 1500 x 109/mL ; platelet count &gt; 100,000 x 109/mL 4 . Hepatic function : serum albumin &gt; 3.0 g/dL ; aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) &lt; 3x upper limit normal ( ULN ) ; alkaline phosphatase &lt; 2x ULN 5 . Prothrombin time ( PT ) partial thromboplastin time ( PTT ) &lt; 1.4x ULN 6 . Calculated creatinine clearance &gt; 50 mL/minute ( Appendix 3 ) 7 . At least 18 year age 8 . Willing able give inform consent adhere protocol therapy 9 . Karnofsky performance status ( KPS ) &gt; =70 % 10 . Able willing use medically acceptable form pregnancy prevention 11 . Negative urine/serum pregnancy test , applicable 1 . Prior surgery , radiation therapy , chemotherapy biopsy emergency procedure require supportive care oral cavity cancer . 2 . Any medical contraindication previous therapy would preclude treatment either IRX 2 Regimen 1 2 surgery , reconstruction adjuvant therapy require treat oral tumor appropriately 3 . Clinical status either subject tumor administration 21 day neoadjuvant IRX2 Regimen 1 2 surgery would medically inappropriate 4 . Tumor oropharynx 5 . Other clinical issue would make participation clinical trial inappropriate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Head Neck Neoplasms</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Cancer</keyword>
	<keyword>Oral Cavity</keyword>
</DOC>